VIA
ACAD icon

Virtus Investment Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Virtus Investment Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
55,139
+24,044
+77% +$529K 0.33% 135
2026
Q1 		$692K Buy
31,095
+5,925
+24% +$142K 0.19% 179
2025
Q4 		$672K Buy
25,170
+4,729
+23% +$113K 0.18% 190
2025
Q3 		$436K Hold
20,441
– – 0.12% 218
2025
Q2 		$441K Sell
20,441
-363
-2% -$6.75K 0.15% 204
2025
Q1 		$346K Sell
20,804
-18,566
-47% -$337K 0.09% 228
2024
Q4 		$722K Buy
+39,370
New +$635K 0.57% 42

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtus Investment Advisers's ACAD Position: Q2 2026 in Review

Virtus Investment Advisers increased its Acadia Pharmaceuticals (ACAD) stake by 77% in Q2 2026, buying an estimated $529K and bringing the position to 55,139 shares worth $1.4M. The position accounts for 0.33% of the portfolio, ranked #135.

Virtus Investment Advisers first reported a position in ACAD in Q4 2024 and has held it in 7 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Virtus Investment Advisers held 55,139 shares of Acadia Pharmaceuticals worth $1.4M as of Q2 2026.
  • Virtus Investment Advisers bought 24,044 Acadia Pharmaceuticals shares in Q2 2026, an estimated $529K.
  • Acadia Pharmaceuticals made up 0.33% of Virtus Investment Advisers's portfolio in Q2 2026, its #135 holding.
  • Virtus Investment Advisers first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.